banner2

Getting started
Sorafenib Free Base

Sorafenib Free Base - China Manufacturers, Suppliers, Factory

Sorafenib Free Base, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Irinotecan 97682-44-5 — Irinotecan Free Base CAS 97682-44-5 Assay ≥99.0% (HPLC) API Factory High Purity
Read More

Dess-Martin Periodinane CAS 87413-09-0 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Dess-Martin Periodinane CAS 87413-09-0 (DMP) Assay >98.0% (Base on Theoxidation) Factory

CAS 231277-92-2 Purity 99.5 (HPLC) API Factory Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Lapatinib Base CAS 231277-92-2 Purity ≥99.0% (HPLC)

Sorafenib Tosylate CAS 475207-59-1 Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Sorafenib Tosylate CAS 475207-59-1 Purity ≥99.0% (HPLC) API Factory High Quality

4-(4-Aminophenoxy)-N-Methyl-2-Pyridinecarboxamide CAS 284462-37-9 — 4-(4-Aminophenoxy)-N-Methylpicolinamide CAS 284462-37-9 Sorafenib Tosylate Intermediate Factory High Purity

4-Chloro-N-methyl-2-pyridinecarboxamide CAS 220000-87-3 — 4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS 220000-87-3 Sorafenib Tosylate Intermediate Factory High Purity

Epitalon CAS 307297-39-8 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Epitalon CAS 307297-39-8 Purity ≥98.0% (HPLC) High Purity

banner4

Top Selling Products

Related Blog
Reviews

Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Understanding Fluorouracil Testing and analysis

Fluorouracil, a compound with a molecular weight of 130.08, is necessity in the pharmaceutical industry. It is crucial to handle Fluorouracil with care to prevent inhalation and skin exposure. spec...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Summit

The one-third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum take topographic point from November 19 to 21, 2021. China’s large...

2022.09.12 09:09:12
2022.08.25 02:13:20
2022.04.29 09:30:51
2022.03.28 23:15:47
2022.02.02 16:15:13
2022.01.21 01:36:29

related search